|
|
Article: Pfizer Expands Commitment to Urology With Agreement to Acquire Worldwide Rights to New Drug Candidate Fesoterodine.
- Article from:
- PR Newswire Europe
- Article date:
- April 13, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW YORK, April 13 /PRNewswire/ --
- New Treatment Expected to Provide Additional Choice for Overactive Bladder Patients
Pfizer Inc said today that it has entered into an agreement with Schwarz Pharma AG under which Pfizer will acquire exclusive worldwide rights to fesoterodine, a new drug candidate for treatment for overactive bladder.
Earlier this year, Schwarz submitted new drug applications for fesoterodine with both the US Food and Drug Administration and the European Medicines Evaluation Agency (EMEA).
"Overactive bladder is a debilitating condition that affects up to 100 million people around the world," said Karen Katen, vice ...